Ruey-ching (Richard) Hwang, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ruey-ching (Richard) Hwang, PhD


Ruey-ching (Richard) Hwang, PhD
Senior Director,
Pharmaceutical Sciences
Pfizer Global R&D

Richard (Ruey-ching) Hwang is senior director of clinical supply manufacturing at Pfizer and has been with the company since 2003. He previously held positions at Pharmacia, Mallinckrodt, and G.D. Searle.

Hwang has authored and/or coauthored nearly 20 papers, given nearly 40 presentations and training courses, and presented more than 20 posters at poster sessions. He is a member of the American Association of Pharmaceutical Scientists (AAPS) and is a member of Pharmaceutical Technology’s Editorial Advisory Board.

He holds an MBA from the Keller Graduate School of Management at DeVry University and a PhD in Pharmaceutics from the College of Pharmacy at the University of Iowa. He received his BS in Pharmacy from the School of Pharmacy, College of Medicine, National Taiwan University.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here